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ABSTRACT
Introduction A lapse (any smoking) early in a smoking 
cessation attempt is strongly associated with reduced 
success. A substantial proportion of lapses are due to 
urges to smoke triggered by situational cues. Currently, no 
available interventions proactively respond to such cues 
in real time. Quit Sense is a theory- guided just- in- time 
adaptive intervention smartphone app that uses a learning 
tool and smartphone sensing to provide in- the- moment 
tailored support to help smokers manage cue- induced 
urges to smoke. The primary aim of this randomised 
controlled trial (RCT) is to assess the feasibility of 
delivering a definitive online efficacy trial of Quit Sense.
Methods and analyses A two- arm parallel- group 
RCT allocating smokers willing to make a quit attempt, 
recruited via online adverts, to usual care (referral to the 
NHS SmokeFree website) or usual care plus Quit Sense. 
Randomisation will be stratified by smoking rate (<16 vs 
≥16 cigarettes/day) and socioeconomic status (low vs 
high). Recruitment, enrolment, baseline data collection, 
allocation and intervention delivery will be automated 
through the study website. Outcomes will be collected at 
6 weeks and 6 months follow- up via the study website 
or telephone, and during app usage. The study aims to 
recruit 200 smokers to estimate key feasibility outcomes, 
the preliminary impact of Quit Sense and potential cost- 
effectiveness, in addition to gaining insights on user views 
of the app through qualitative interviews.
Ethics and dissemination Ethics approval has been 
granted by the Wales NHS Research Ethics Committee 
7 (19/WA/0361). The findings will be disseminated to 
the public, the funders, relevant practice and policy 
representatives and other researchers.
Trial registration number ISRCTN12326962.
INTRODUCTION
Tobacco smoking is the second largest 
contributor of disease burden globally1 and 
the largest in the UK.2 While quitting reduces 
the risk of smoking- related health problems 
and improves mental health,3 4 the success 
rate remains low. Of the three million UK 
smokers attempting to quit annually, over 
80% relapse within 12 months.5
Almost half of all lapses (any smoking) 
during a quit attempt are attributed to 
cravings triggered by environmental or 
situational cues6 and lapses early in a quit 
attempt are highly predictive of longer- term 
relapse.7–9 However, the most commonly used 
cessation medications do not alleviate cue- 
induced cravings.10 11 Furthermore, while 
smokers are less likely to lapse if they use an 
effective cognitive and/or behavioural lapse 
prevention strategy,10 12 13 few do so.12 14 There 
is a need for cessation interventions that 
effectively support the management of cue- 
induced cravings.
Unlike traditional cessation interventions, 
smartphone apps have the advantage of 
portability and could therefore better assist 
with cue- induced cravings as they occur. 
Some mobile phone- based interventions 
have features specifically aimed at reducing 
lapse risk. Such support can be triggered by 
random Ecological Momentary Assessment 
Strength and limitations of this study
 ► This is the first randomised controlled trial to evalu-
ate a context- aware just- in- time adaptive interven-
tion for smoking cessation.
 ► The study will identify key parameters to inform a 
definitive trial and will estimate intervention im-
pact on biochemically validated abstinence from 
smoking.
 ► Recruitment, enrolment, baseline data collection, al-
location, intervention delivery and most data collec-
tion during follow- up will be fully automated through 
the study website.
 ► There is potential for selection bias due to the re-
quirement for participants to have internet access 
and an Android smartphone.
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prompts15 (where the smartphone prompts the user to 
complete assessment questions); or it can take the form 
of on- demand (ie, user- initiated) requests for craving 
support.16 17 However, given the rapid time to lapse after 
craving onset10 and that many on- demand craving tools 
are seldom used beyond a first try,17 18 these kinds of user- 
initiated features may still miss many craving episodes.
To address such limitations in current digital support, 
we developed Quit Sense, a digital intervention which 
predicts and adapts to smoking risk in real time19 (a just- in- 
time adaptive intervention). Quit Sense is a theory- guided 
smoking cessation tool that delivers ‘context- aware’ lapse 
prevention support primarily using smartphone location 
sensing. It has demonstrated feasibility in delivering ‘in 
the moment’ support and acceptability among users.20 We 
are now conducting a feasibility randomised controlled 
trial (RCT) of Quit Sense to inform the design parame-
ters of a future RCT and to provide estimates of interven-
tion impact.
This trial is being conducted during the COVID-19 
pandemic and as such different contextual variables may 
impact on study participants during their quit attempts 
(eg, self- isolation, remote working) compared with 
before the COVID-19 pandemic. Through qualitative 
interviews and app recorded feedback, this feasibility trial 
will capture participant views of the acceptability of the 
app and study, including how these are impacted by any 
COVID-19 restrictions.
Objectives
In this feasibility trial, we aim to estimate: (a) completion 
rates for the anticipated primary outcome for a full trial, 
(b) usual care arm cessation rate, (c) cost of recruitment 
using online advertising, (d) rates of app installation 
and use, and support delivery fidelity, (e) completion of 
smoking cessation- related resource use and quality of life 
(QoL) data, (f) participant views of the app, as part of a 
qualitative process evaluation, (g) intervention effect on 
anticipated primary outcome and (h) intervention effect 




A two- arm parallel- group randomised controlled feasi-
bility trial, allocating smokers to either ‘usual care’ (link 
to NHS SmokeFree website)21 or the intervention arm 
who receive ‘usual care’ plus access to the Quit Sense app.
Additionally, there is a nested qualitative process eval-
uation with a subsample of control and intervention 
participants to (1) assess intervention experiences and 
how these might help explain causal pathway(s) towards 
smoking behaviour change (intervention arm only)22 and 
(2) asses experiences of study participation.
Additional information on study configuration can be 
found in online supplemental appendix 1.
Participants
Eligibility criteria
Participants will be smokers aged 16 years plus; currently 
smoke at least seven cigarettes per week; willing to make a 
quit attempt within 14 days of enrolling; have primary use 
of an Android smartphone (version 5.0 and above) and 
will be resident in England. Participants must not have 
previously participated in this trial.
Study setting
Participants will complete screening, consent, base-
line and follow- up measures online. This online design 
matches the ‘real world’ setting of smartphone app 
uptake.
Online recruitment
Recruitment is through paid- for online advertisements 
with Google Search and social media (Facebook and 
Instagram), limited to England- based IP addresses and 
targeted at Android devices. Advertisements are managed 
by ‘Nativve’,23 specialists in digital marketing for research 
study recruitment. To maximise participation rate effi-
ciency and in accordance with patient and public involve-
ment (PPI) recommendations, different adverts will be 
tested using A/B experiments while recruitment is live. 
People clicking on adverts will be directed to the study 
website and provided with study information including 
a downloadable ‘Participant Information Sheet’. The 
screening and consent procedures are online with an e- sig-
nature confirming consent (table 1 and online supple-
mental appendix 2). After completing an online baseline 
questionnaire, participants will be randomly allocated to 
usual care or usual care plus Quit Sense. As described in 
figure 1 and informed by a prior text message smoking 
cessation intervention,24 we estimate that ~6625 unique 
visitors are required to achieve a sample size of 200.
The distribution of socioeconomic status (SES) during 
recruitment will be monitored. Low SES is defined as indi-
viduals with a semiroutine or routine and manual occu-
pation, class 5 in the National Statistics Socio- Economic 
Classification (NS- SEC),25 or who have never worked or 
are long- term unemployed. Targeted advertising will be 
used to increase low SES representation if less than 45% 
of our sample are categorised as low SES when 35% of the 
target sample is reached.
Procedure
Both arms will automatically receive a link to NHS Smoke-
Free via SMS after enrolment. Only the Quit Sense arm 
will receive an SMS with an app link and activation code. 
Use of the activation code will be monitored. Participants 
who do not initiate the app will be sent an SMS reminder 
3 days postenrolment and then 5 days postenrolment 
asking to identify a reason for not initiating the app from 
a predefined list.
To attempt to increase response rates, all participants 
will receive an SMS prior to receiving links to follow- up 
questionnaires. Those who do not respond to the SMS 
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with a survey link will be telephoned. Once the 6- week 
questionnaire is completed, a subsample of participants 
from both arms (approximately 3:1 ratio between Quit 
Sense and usual care) will be invited to a telephone inter-
view to gather data on their experiences of the app (inter-
vention only) and of participating in the study. Where 
practicable, we will use purposive sampling to interview a 
mixture of high and low SES abstainers and smokers, and 
for Quit Sense participants based on varying rates of app 
engagement. We anticipate interviewing 20 participants, 
depending on when data saturation is reached.
Six months and 2 weeks after enrolling (allowing for a 
2- week quitting preparation period for Quit Sense partici-
pants; henceforth, referred to as the ‘6- month’ follow- up), 
all participants will be asked via SMS to complete the final 
questionnaire. Participants reporting abstinence in the 
previous 7 days at follow- up will be posted a saliva sample 
kit to be returned to ABS laboratories, UK.
Participants will receive vouchers on completion of the 
6- week (£5) and 6- month (£10) surveys, return of the 
saliva sample (£5) and for participating in an interview 
(£20).
Table 1 Schedule of participant assessments and intervention delivery
Study period
  Enrolment (online) Allocation (online)
Postallocation (online or 
telephone)
Close- out (online or 
telephone)
Timepoint 0 0
*6 weeks FU (from 
enrolment)
†6 months FU (from 
enrolment)
Enrolment:         
Eligibility screen X       
Informed consent X       
Allocation X     
Interventions:       
Usual care (link to www.
smokefree.nhs.uk)
  X     
Quit Sense app+usual care   X   
Assessments:       
Demographics X     
Use of smartphone and apps X     X
Smoking behaviour and 
dependence
X   X
Smoking beliefs X     X
Cessation self- efficacy X   X X
Strength and frequency of urges 
to smoke
X   X X
Automaticity and associative 
processes subscales of the 
WISDM-37
X   X   
EQ- 5D- 5L X     X
Smoking lapse incidence     X   
Smoking abstinence outcomes     X X
Use of lapse prevention 
strategies
    X   
Smoking cessation resource use       X
Views on the app (Quit Sense 
arm only)
      X
Assessment of tobacco 
exposure (postal saliva sample)
      X
*Follow- up at 6 weeks (1 month, plus 2 weeks to cover the likely quitting period/phase 1 of the app).
†Follow- up will be scheduled approximately 6 months postenrolment in the study, allowing for an additional 2 weeks to cover the likely 
quitting period (phase 1 of the app). Although in practice this will be 6 months plus 2 weeks, we will refer to it simply as the ‘6- month follow- 
up’ for convenience.
EQ- 5D- 5L, quality of life; FU, follow- up; WISDM-37, Wisconsin Inventory of Smoking Dependence Motives.
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As suggested by our PPI panel, all participants will 
receive a postcard and SMS to thank them and emphasise 
their importance to the study.
Criteria for discontinuing or modifying allocated interventions
Unless a participant withdraws from the study, they will be 
followed- up for data collection regardless of their level of 
engagement or smoking status. Participants, who discon-
tinue using the app for any reason other than withdrawal, 




Usual care is a web- link (NHS SmokeFree) sent by 
SMS. We consider this equivalent to ‘usual care’ for an 
online population. SmokeFree provides access and sign-
posting to digital, telephone and in- person cessation 
support in England. At the time of writing, the support 
offered includes information and links to six main types 
of support; support from a cessation advisor (via a Stop 
Smoking Service), the SmokeFree National telephone 
helpline, an online chat facility with an advisor, an email 
cessation programme, an SMS text message programme 
and the NHS SmokeFree smartphone app (28- day 
programme, non- tailored and not including proactive 
support delivery for managing urges to smoke).
Quit sense APP arm
Quit Sense is a context- aware smartphone app designed 
for smokers wanting to quit. It is informed by learning 
theory (LT)26 27 and two theory- guided SMS text message 
systems,17 28 which are in turn informed by social cogni-
tive theory (SCT).29 Quit Sense targets three key deter-
minants that map onto LT and six mapping onto SCT: 
learnt associations between smoking and an individual’s 
physical environment (LT); learnt associations between 
Figure 1 Flow diagram showing study design, measures and sample sizes.
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smoking and mood triggered by the environment (LT); 
the presence of other smokers (LT, SCT); awareness of 
smoking triggers (antecedents) (SCT); outcome expec-
tancies of a lapse (SCT); goal/intention for complete 
abstinence (SCT); self- efficacy in resisting urges to smoke 
(SCT); knowledge of and self- efficacy for lapse preven-
tion strategy use (SCT). Twenty- one corresponding 
behaviour change techniques (BCTs)30 are used to target 
these determinants.
The main feature is ‘Geofence- Triggered Support’ 
(GTS), which is orientated around three app stages:
 ► Stage 1 (training): the user sets a quit date (default 
suggestion 7 days) and trains the app to learn about 
their smoking behaviour. This requires the user to 
report in the app each smoking episode and the situa-
tional context in real time (stress, mood, urge strength, 
setting description (home, working, home- working, 
socialising, other), presence of other smokers), while 
the app records geolocation. If a user reports smoking 
more than once in the same location (as defined by 
the app), a geofence (a circular virtual perimeter) is 
created representing a high- risk area. Location moni-
toring precision varies depending on the availability 
of GPS/WiFi/network (range ~5–50 m).
 ► Stage 2 (28- day abstinence challenge): postquit date, 
the app monitors the user’s location. A support message 
is triggered a minimum of 1 min after the user enters a 
geofence zone (typical range 1–15 min, depending on 
operating system). Messages are individually tailored 
using stage 1 context information and using any stage 
2 smoking reports, providing support to help users 
avoid or cope with location specific triggers. Further 
messages are triggered after each 3- hour interval of 
remaining in that location (default between 8 am and 
9.30 pm or as defined by the user). This also applies 
to ‘home- working’ messages. However, if the user has 
not reported ‘home- working’ within the time window 
(2–3 hours) in which the message is to be delivered, 
a ‘home’ message will be delivered instead. This is 
because ‘time’ of reporting is an additional require-
ment (to ‘location’) for home- working messages to be 
triggered.
 ► Stage 3 (maintaining abstinence): the app continues 
to deliver GTS for two further months but reduces the 
frequency by one- half every month. After 3 months 
postquit date, the GTS support stops, unless the user 
opts to switch it back on or restart their quit attempt.
Quit Sense has six additional features (relevant to all 
stages, unless specified otherwise):
1. Feedback is provided after each smoking report. In 
stage 1 this is tailored to nine characteristics collect-
ed during app initiation. Messages focus on enhanc-
ing quitting preparation, motivation and self- efficacy. 
In stage 2, feedback is non- tailored and orientated 
around lapse and relapse prevention.
2. An ‘End of Day’ (EoD) survey that users are prompt-
ed to complete, recording cigarettes smoked that day, 
cravings31 and self- efficacy28 29 (stages 1 and 2 only). 
Feedback is provided after each EoD survey, includ-
ing encouragement to log smoking behaviour if there 
is a discrepancy between the survey and real time re-
ports.
3. A ‘my profile’ screen including number of days quit, 
money saved (based on smoking rate and reported 
cost), a calendar showing a heat map and ‘smileys’ 
(use of yellow, grey and blue to denote values with 
corresponding happy, neutral and sad smileys) for 
smoking, cravings and self- efficacy for each EoD sur-
vey completed. In addition, smoking pattern feedback 
is provided using graphical and written summaries for 
smoking triggers based on the user’s historical report-
ing.
4. A ‘library’ of quitting advice split into six categories: 
‘getting ready’, ‘boost your motivation’, effects of 
smoking and quitting’, ‘early days of quitting’, ‘staying 
quit’, ‘smoking after your quit date’. Users can write 
and submit their own support messages.
5. Scheduled non- tailored daily support messages deliv-
ered each morning orientated around the quit date 
(stages 1 and 2 only)—targeting outcome expectan-
cies, motivation, preparation, self- efficacy (three sets 
of different messages to prevent message duplication 
in successive attempts).
6. The option for the user to reset their quit date in stage 
1, if they are not feeling ready, or stage 2 if they re-
lapse. Relapse is defined as multiple smoking episodes 
that are reported over 2 days during a quit attempt (ei-
ther through smoking episode logs or the EoD survey). 
If this occurs, users are invited to either recommit and 
continue or reset their quit date and return to Stage 1.
Qualitative process evaluation
The aims of the qualitative process evaluation are:
1. To gather user experiences of app usage in order to 
inform app optimisation.
2. To understand participant experiences of participa-
tion and the unique contexts in which participants are 
attempting to quit.
Interview questions will probe for in- depth descrip-
tions of intervention participants’ experiences of app 
usage including which types of support they liked most 
and least, the timing of support in relation to experi-
enced need for support, and views on the features used. 
Control participants will be asked about their experience 
of trial participation. Both groups will be asked about 
their use of or interest in other smoking cessation aids 
and support and contextual details such as mandated 
movement restrictions and family setting. In addition, the 
Quit Sense app includes an in- built audio record feature 
so that users can leave feedback. The study will therefore 
also assess the feasibility of a user- initiated process evalua-
tion approach where data are collected with high ecologi-
cally validity. Any relevant data submitted will be analysed 
alongside interview data, potentially providing a broader 
range of views from a more user- controlled perspective. 
Transcriptions from interviews or app recordings will be 
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anonymised. Recordings will be deleted after transcrip-
tion, or if not fully transcribed, after audio coding for 
analysis.
Database
Study data are collected and managed using REDcap 
(Research Electronic Data Capture) tools hosted at 
Norwich Clinical Trials Unit. REDcap is a secure, web- 
based software platform supporting data capture for 
research studies.32 33 Further details on data management 
can be found in the online Supplementary File.
Outcomes
Feasibility outcomes
As this is a feasibility trial, there is no primary outcome. 
Feasibility outcomes will be used to estimate key parame-
ters to inform a future trial,34 and include:
1. Completeness of the anticipated primary outcome for 
a future definitive trial (6- month self- reported absti-
nence with biochemical validation; see smoking out-
comes section).
2. Abstinence rate of usual care arm, using the anticipat-
ed primary outcome for a future definitive trial.
3. Cost per recruit, based on advertising costs.
4. Rates of app installation use and support delivery fi-
delity.
5. Completion of smoking cessation- related resource use, 
including usual care use and quality of life (EQ- 5D- 
5L)35 data.
6. Hypothesised mechanisms of action of Quit Sense.
7. Participant experiences and feedback on app usage.
Smoking and related outcomes
Smoking and related outcomes will provide preliminary 
information about the intervention’s impact. The main 
abstinence outcome for which we will monitor complete-
ness of ascertainment is based on the Russell standard.36 
Abstinence will be defined as self- reported abstinence in 
the previous 6 months allowing for no more than five ciga-
rettes and not smoking in the previous week, biochemi-
cally validated by a saliva cotinine concentration of less 
than 10 ng/mL36 37 and for those using nicotine substitu-
tion (eg, Nicotine Replacement Therapy, or e- cigarettes) 
an anabasine concentration of less than 0.2 ng/mL, based 
on feedback from our testing laboratory.37 38 Thresholds 
will be reviewed prior to analysis in case of changes in 
guidance or relevant evidence. Given recent evidence that 
some e- liquid, believed to be that made outside of the UK, 
can contain anabasine,37 we will monitor the proportion 
of e- cigarette users who report abstinence from smoking 
but have an anabasine level above the chosen threshold.
Smoking cessation experts highlight the value of addi-
tional smoking outcomes based on different time periods 
of abstinence and time- points.39 We will therefore measure 
7- day point prevalence abstinence at 6 months follow- up 
(self- report and biochemically verified) and 7- day point 
prevalence abstinence at 6 weeks follow- up (self- report).
We will collect the following hypothesised mechanisms 
of action at 6- week follow- up:
 ► Lapse incidence (any smoking, even a puff) since the 
initial quit attempt (if made),6 which is highly predic-
tive of relapse.7–9
 ► Lapse prevention strategy use,14 which is associated 
with lapse prevention.10
 ► Self- efficacy,28 29 which prospectively predicts lapse 
and relapse to smoking.40
 ► The strength of urges to smoke measure,31 which 
prospectively predicts abstinence and is superior to 
other urge- measures in doing so,41 and frequency of 
urges to smoke.41
 ► Automaticity and associative processes subscales from 
the Wisconsin Inventory of Smoking Dependence 
Motives (WISDM-37).42
Sample size
In line with recommendations that feasibility studies with 
binary outcome measures recruit at least 60 participants 
per group (minimum of 120) and a maximum of 100 
per group, the proposed sample size for this trial is 200 
smokers (100 per arm).43 Participants will be randomised 
to usual care or Quit Sense arms on a 1:1 ratio. This 
sample size will enable key parameters to inform a future 
definitive trial to be estimable within the following preci-
sion (defined as the 95% CI half- width):
 ► Primary outcome completion: we estimate a follow- up 
rate for self- reported smoking status at 6 months of 
80%, with precision of ±6%.44–46 For biochemical vali-
dation, we estimate that 75% of participants reporting 
abstinence will return a saliva sample by post, with 
precision of ±22%.28 45
 ► Cessation rate in usual care arm: we estimate an absti-
nence rate of 5% at 6 months follow- up, providing 
precision of±4%.47
 ► App installation and initiation: we estimate that 85% 
of intervention participants will instal the app, with 
precision of±7%.48
 ► App engagement—in our acceptability study, 71% 
used the app for more than 1 week (a timeframe 
deemed meaningful by our PPI panel). With a similar 
rate in the trial, precision would be ±9%. This is in 
line with other studies.48
Randomisation
Sequence generation, allocation and blinding
Randomisation will be stratified by smoking rate (<16 vs 
≥16 cigarettes/day; based on mean smoking rates from 
trials recruiting smokers online)45 49 and SES (low vs 
high), based on the NS- SEC self- coded method.50 Allo-
cation sequences will be generated by a computer- based 
random number generator using random permuted 
blocks (varying block sizes) (using REDcap). Randomi-
sation will be integrated into the enrolment process on 
the study website. The system will not permit a partici-
pant to enrol twice with the same mobile number or 
email address. As allocation will be integrated into the 
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study website, the allocation sequence will be concealed 
from participants until assignment and concealed from 
members of the trial team, except the statistician, devel-
opers of the study database and the research associate 
supporting trial delivery.
Data analysis
The feasibility and acceptability of all measures will be 
assessed by their level of completeness and via interviews 
and app audio data.
Outcomes
Completeness of the anticipated primary outcome for 
a future trial (outcome i) and the abstinence rate using 
this anticipated primary outcome for the usual care arm 
(outcome ii) will be described as proportions with 95% 
CIs, and translated into interpretable probabilities using 
the Bayesian approach relevant in preliminary trials with 
the objective of powering the definitive trial.
Cost per recruit (outcome iii), rates of app installa-
tion (outcome iv) and completion of smoking cessation- 
related resource use and EQ- 5D- 5L (outcome v) will be 
described using summary statistics with 95% CIs.
We will estimate the preliminary intervention effect on 
abstinence, lapse incidence and use of lapse prevention 
strategies, using multiple logistic regression, providing 
ORs with 95% CIs, while adjusting for any potential base-
line confounders defined by the statistical analysis plan 
(SAP). For the estimated intervention effect on absti-
nence, we will assume missing=smoking.36 To estimate 
intervention effects on self- efficacy, urges and smoking 
dependence motives, we will use analysis of covariance 
models involving adjustment for the baseline score and 
for predefined potential confounders, primarily using 
complete cases only. Missing outcome assumptions will be 
assessed through sensitivity analyses which will be defined 
in the SAP.
Economic evaluation
We aim to collect data (baseline and 6- months follow- up) 
that will enable us to inform the decision as to how cost 
(based on resource use data) and benefit (in terms of 
QoL) data are estimated in any future more definitive 
study. Completion rates will thereby be estimated.
In terms of costs, we will estimate those associated with 
the intervention (eg, app maintenance) and smoking 
related costs to both the individual (eg, nicotine replace-
ment therapy) and the NHS (eg, NHS stop smoking 
services/GP visits). In line with National Institute for 
Health and Care Excellence (NICE) guidance,51 QoL 
will be measured via the EQ- 5D- 5L35 as this enables the 
calculation of QALY (Quality Adjusted Life Year) scores. 
Appropriate unit costs52 will also be attached to all items 
of resource- use in order to identify major cost drivers.
Based on the intention to treat approach, a preliminary 
cost- effectiveness analysis will be performed. In the base- 
case analysis, costs will be estimated from the viewpoint of 
the NHS and personal social services.51 We will estimate 
the mean incremental cost and mean QALY gain associ-
ated with Quit Sense compared with usual care. Assuming 
dominance does not occur (where one intervention is 
both more costly and less effective), then the incremental 
cost effectiveness ratio (incremental cost/QALY gain) 
will be estimated and assessed in relation to a range of 
cost- effectiveness thresholds (eg, £20 000 to £30 000 per 
QALY),51 in order to provide a preliminary assessment of 
whether Quit Sense constitutes value for money. The asso-
ciated level of uncertainty will also be estimated.
Qualitative process evaluation data collection and analysis
Interviews will be audio- recorded and transcribed intelli-
gent verbatim. App audio- recordings may be transcribed 
depending on quality and resources. If transcription is 
unfeasible, coding of audio files will be completed.
We will undertake an inductive thematic analysis of 
the first 3–4 interview transcripts,53 develop a coding 
framework from this and then code remaining data. We 
will check coding consistency through the independent 
coding of 10% of the data, with a further 10% if consis-
tency is unsatisfactory. We will continue refining until the 
themes are agreed.
Analysis of process evaluation data will focus on identi-
fying key themes associated with using the app and views 
and experiences of using other relevant apps. A second 
stage of analysis will work with descriptions of experiences 
of lapse or lapse avoidance in the context of the app and 
considering unique participant contexts. These will be 
reported as vignettes and used to explore participant 
experiences and to identify mechanisms of action and 
casual pathways towards behaviour change.
Patient and public involvement
We have a PPI panel of four former smokers who have 
contributed to study design including the recruitment 
strategy, wording of SMS messages, study information, 
the qualitative evaluation, the design of the study logo 
and the function and features of the Quit Sense app and 
support it delivers. The PPI panel is represented on the 
Trial Steering Committee.
DISCUSSION
A feasibility trial of Quit Sense will identify the conditions 
necessary for a definitive trial, including for successful 
study design and data collection. This will largely be 
determined by whether the recruitment strategy is able to 
produce the required sample size and participant reten-
tion rates; the rate of app installation; completion rates 
for follow- up and the anticipated primary outcome for a 
full trial and participant views of the acceptability of the 
app and study. A potential future RCT will enable us to 
establish the extent to which the Quit Sense app is effec-
tive and cost effective relative to the usual provision of 
online stop smoking support.
This remotely delivered and largely automated trial 
is being conducted during the COVID-19 pandemic, 
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a time when health protection measures are restricting 
or preventing many everyday behaviours. As such, there 
are likely to be different contextual variables impacting 
on study participants (eg, self- isolation, remote working, 
limited opportunities to socialise, etc.) compared with 
before the pandemic. The Quit Sense app can learn about 
such situational factors because of the initial training 
phase where the user reports on their smoking behaviour. 
Furthermore, we hope to capture in- depth insights into 
the unique contexts in which participants are attempting 
to make their quit attempts through telephone interviews 
and the app’s inbuilt audio- record feature.
The potential of intelligent and ‘always on’ digital 
cessation tools in providing on- hand effective and low 
cost support means that they are likely to be of growing 
importance in enhancing chances of successful quitting.54 
However, measures are needed to realise the potential 
of next generation digital cessation interventions most 
of which remain untested.15 Where app evaluations 
have been undertaken results show that evidence- based 
smoking cessation strategies are underutilised,55 that 
many use a limited number of BCT,56 57 and that few use 
features such as geolocation or just- in- time sensors.56 
It is crucial, therefore, that their effectiveness and cost 
effectiveness are established, particularly through use of 
randomised control trials.58
Quit Sense has been developed to address many of 
the current limitations in digital support. The app is 
distinct from other cessation support available due to its 
ability to identify location- based high- risk locations using 
smartphone sensing to provide timely theory- guided 
and tailored ‘in- the- moment’ support. Quit Sense has 
been developed to help smokers avoid or manage urges 
to smoke triggered by cues within these high- risk loca-
tions. This is done through the provision of lapse preven-
tion strategies, outcome expectancy management and 
motivational and self- efficacy enhancement. Ultimately, 
this support aims to help extinguish learnt associations 
between smoking and a person’s physical, social and 
psychological environment in order to reduce future 
relapse risk.
Ethics and dissemination
Ethics approval has been granted by the Wales NHS 
Research Ethics Committee 7 (19/WA/0361). The find-
ings will be disseminated to the public, the funders, 
relevant practice and policy representatives and other 
researchers. A fully anonymised data set from the trial will 
be made available on reasonable request.
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